China Shineway Pharmaceutical Group Limited Net Asset Quality Index
China Shineway Pharmaceutical Group Limited net asset quality index. China Shineway Pharmaceutical Group Limited (C1S) has a Net Asset Quality Index of 74.8% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €10.78 Billion minus total liabilities of €2.72 Billion yields net assets of €8.06 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See C1S book value for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of China Shineway Pharmaceutical Group Limited (2013–2025)
Net asset quality index of China Shineway Pharmaceutical Group Limited from 2013 to 2025. This chart shows how China Shineway Pharmaceutical Group Limited's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of December 2025, the index stands at 74.8%, representing net assets of €8.06 Billion against total assets of €10.78 Billion EUR. Check strategic asset allocation of China Shineway Pharmaceutical Group Limi to assess the company's strategic physical and investment asset allocation.
China Shineway Pharmaceutical Group Limited Net Asset Quality Index by Year (2013–2025)
China Shineway Pharmaceutical Group Limited net asset quality index by year from 2013 to 2025. The table below presents the year-by-year Net Asset Quality Index for China Shineway Pharmaceutical Group Limited from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see market cap of China Shineway Pharmaceutical Group Limi.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 74.8% | €8.06 Billion | €10.78 Billion | €2.72 Billion | ▲ +0.4 pp |
| 2024 | 74.4% | €7.47 Billion | €10.04 Billion | €2.57 Billion | ▲ +0.9 pp |
| 2023 | 73.5% | €7.03 Billion | €9.57 Billion | €2.54 Billion | ▼ -4.1 pp |
| 2022 | 77.5% | €6.38 Billion | €8.23 Billion | €1.85 Billion | ▼ -4.4 pp |
| 2021 | 81.9% | €5.90 Billion | €7.20 Billion | €1.30 Billion | ▲ +1.6 pp |
| 2020 | 80.3% | €5.79 Billion | €7.21 Billion | €1.42 Billion | ▼ -0.7 pp |
| 2019 | 81.0% | €5.78 Billion | €7.13 Billion | €1.35 Billion | ▼ -4.6 pp |
| 2018 | 85.7% | €5.77 Billion | €6.73 Billion | €966.01 Million | ▼ -1.7 pp |
| 2017 | 87.3% | €5.82 Billion | €6.67 Billion | €844.16 Million | ▲ +0.3 pp |
| 2016 | 87.0% | €5.63 Billion | €6.47 Billion | €838.59 Million | ▲ +1.0 pp |
| 2015 | 86.1% | €5.30 Billion | €6.15 Billion | €857.13 Million | ▲ +3.2 pp |
| 2014 | 82.8% | €4.89 Billion | €5.91 Billion | €1.01 Billion | ▲ +5.6 pp |
| 2013 | 77.2% | €4.43 Billion | €5.74 Billion | €1.31 Billion | — |